Scientific publications

Production and use of adeno-associated virus vectors as tools for cancer immunotherapy

Jan 1, 2020 | Magazine: Methods in Enzymology

Myriam Fernandez-Sendin, Shirley Tenesaca, Marcos Vasquez, Fernando Aranda, Pedro Berraondo


Recombinant adeno-associated viruses (rAAVs) are attractive tools for research in cancer immunotherapy. A single administration of an AAV vector in tumor mouse models induces a progressive increase in transgene expression which reaches a plateau 1 or 2 weeks after administration. The rAAV is then able to maintain the expression of the immunostimulatory transgene. Thus, the use of these vectors obviates the need for frequent administrations of the therapeutic protein to achieve the antitumor effect.

The long-term expression of AAV vectors can be exploited for the evaluation of the antitumor activity of immune-enhancing proteins. Most preclinical studies have focused on the expression of cytokines and on the induction of immune responses elicited by tumor-associated antigens expressed by rAAVs. Notwithstanding, rAAVs may not be suitable for immunostimulatory proteins that require high and/or immediate expression. In this chapter, we review a feasible, reliable and detailed protocol to produce and purify AAV vectors as a tool for cancer immunotherapy strategies.

CITA DEL ARTÍCULO  Methods Enzymol. 2020;635:185-203. doi: 10.1016/bs.mie.2019.05.007.